431 related articles for article (PubMed ID: 24419417)
41. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
42. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
[TBL] [Abstract][Full Text] [Related]
43. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
[TBL] [Abstract][Full Text] [Related]
44. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
45. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
46. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Yoshida T; Ishii G; Goto K; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Nagai K; Ohe Y; Ochiai A
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1691-700. PubMed ID: 23974272
[TBL] [Abstract][Full Text] [Related]
47. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
48. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
49. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
Paz-Ares L; Soulières D; Moecks J; Bara I; Mok T; Klughammer B
J Cell Mol Med; 2014 Aug; 18(8):1519-39. PubMed ID: 25100284
[TBL] [Abstract][Full Text] [Related]
50. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
51. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
52. Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Nishino M; Dahlberg SE; Fulton LE; Digumarthy SR; Hatabu H; Johnson BE; Sequist LV
Acad Radiol; 2016 Mar; 23(3):329-36. PubMed ID: 26776293
[TBL] [Abstract][Full Text] [Related]
53. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
[TBL] [Abstract][Full Text] [Related]
54. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
55. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
56. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
57. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
58. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
59. Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients.
Shaozhang Z; Ming Z; Haiyan P; Aiping Z; Qitao Y; Xiangqun S
Med Oncol; 2014 May; 31(5):926. PubMed ID: 24748405
[TBL] [Abstract][Full Text] [Related]
60. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
